Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00654732
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
PTK/ZK in Disseminated Malignant Melanoma
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Michael Weichenthal
- Target Recruit Count
- 9
- Registration Number
- NCT00615160
- Locations
- 🇩🇪
Dpt. of Dermatology, University of Frankfurt, Frankfurt/Main, Germany
🇩🇪Dpt. of Dermatology, University of Cologne, Koeln, Germany
🇩🇪Dpt. of Dermatology; UK-SH Campus Kiel, Germany, Kiel, Germany
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00600496
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 106
- Registration Number
- NCT00533702
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2015-07-16
- Target Recruit Count
- 360
- Registration Number
- NCT00526318
- Locations
- 🇩🇪
Klinikum Augsburg, Augsburg, Germany
🇩🇪Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
🇩🇪Klinikum Duisburg, Duisburg, Germany
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
- Conditions
- Interventions
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00516802
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00498979
- Locations
- 🇺🇸
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Phase I/II Study of Sunitinib and Dacarbazine
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2011-02-23
- Target Recruit Count
- 11
- Registration Number
- NCT00496223
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Körholz
- Target Recruit Count
- 2134
- Registration Number
- NCT00433459
- Locations
- 🇬🇧
Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom
🇩🇪Universitaetsklinikum Giessen-Marburg, Giessen, Germany
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Körholz
- Target Recruit Count
- 648
- Registration Number
- NCT00416832
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.